JP2015512885A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015512885A5 JP2015512885A5 JP2014560442A JP2014560442A JP2015512885A5 JP 2015512885 A5 JP2015512885 A5 JP 2015512885A5 JP 2014560442 A JP2014560442 A JP 2014560442A JP 2014560442 A JP2014560442 A JP 2014560442A JP 2015512885 A5 JP2015512885 A5 JP 2015512885A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- nhr
- cancer
- present
- saturated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 170
- 229920006395 saturated elastomer Polymers 0.000 claims description 77
- 125000000217 alkyl group Chemical group 0.000 claims description 50
- 229910052757 nitrogen Inorganic materials 0.000 claims description 46
- 125000006413 ring segment Chemical group 0.000 claims description 42
- 125000005842 heteroatom Chemical group 0.000 claims description 37
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 33
- 229910052799 carbon Inorganic materials 0.000 claims description 33
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 30
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 30
- -1 pyrrolidino, piperidino, piperazino, morpholino Chemical group 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- 206010049422 Precancerous skin lesion Diseases 0.000 claims description 19
- 125000002947 alkylene group Chemical group 0.000 claims description 18
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 125000000623 heterocyclic group Chemical group 0.000 claims description 18
- 229910052717 sulfur Inorganic materials 0.000 claims description 17
- 230000003902 lesion Effects 0.000 claims description 15
- 208000011580 syndromic disease Diseases 0.000 claims description 15
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 14
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 11
- 208000024827 Alzheimer disease Diseases 0.000 claims description 10
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 10
- 206010070511 Hypoxic-ischaemic encephalopathy Diseases 0.000 claims description 10
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 208000008589 Obesity Diseases 0.000 claims description 10
- 241000700584 Simplexvirus Species 0.000 claims description 10
- 208000009973 brain hypoxia - ischemia Diseases 0.000 claims description 10
- 230000003683 cardiac damage Effects 0.000 claims description 10
- 201000006902 exudative vitreoretinopathy Diseases 0.000 claims description 10
- 208000030159 metabolic disease Diseases 0.000 claims description 10
- 201000006417 multiple sclerosis Diseases 0.000 claims description 10
- 235000020824 obesity Nutrition 0.000 claims description 10
- 208000033300 perinatal asphyxia Diseases 0.000 claims description 10
- 201000005936 periventricular leukomalacia Diseases 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 10
- 206010058314 Dysplasia Diseases 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 230000007812 deficiency Effects 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 208000007122 AIDS-Associated Nephropathy Diseases 0.000 claims description 5
- 208000022099 Alzheimer disease 2 Diseases 0.000 claims description 5
- 206010004593 Bile duct cancer Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 208000016192 Demyelinating disease Diseases 0.000 claims description 5
- 206010012305 Demyelination Diseases 0.000 claims description 5
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 5
- 208000028506 Familial Exudative Vitreoretinopathies Diseases 0.000 claims description 5
- 206010016654 Fibrosis Diseases 0.000 claims description 5
- 206010070737 HIV associated nephropathy Diseases 0.000 claims description 5
- 208000017604 Hodgkin disease Diseases 0.000 claims description 5
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 5
- 101000663006 Homo sapiens Poly [ADP-ribose] polymerase tankyrase-1 Proteins 0.000 claims description 5
- 101000662592 Homo sapiens Poly [ADP-ribose] polymerase tankyrase-2 Proteins 0.000 claims description 5
- 206010027476 Metastases Diseases 0.000 claims description 5
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 5
- 208000001132 Osteoporosis Diseases 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 102100037664 Poly [ADP-ribose] polymerase tankyrase-1 Human genes 0.000 claims description 5
- 102100037477 Poly [ADP-ribose] polymerase tankyrase-2 Human genes 0.000 claims description 5
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims description 5
- 208000007135 Retinal Neovascularization Diseases 0.000 claims description 5
- 208000022617 SERKAL syndrome Diseases 0.000 claims description 5
- 206010039491 Sarcoma Diseases 0.000 claims description 5
- 206010072610 Skeletal dysplasia Diseases 0.000 claims description 5
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 5
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 5
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims description 5
- 206010047486 Virilism Diseases 0.000 claims description 5
- 230000002159 abnormal effect Effects 0.000 claims description 5
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 5
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 5
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 5
- 230000037182 bone density Effects 0.000 claims description 5
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 208000029078 coronary artery disease Diseases 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 201000004101 esophageal cancer Diseases 0.000 claims description 5
- 230000004761 fibrosis Effects 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 230000004190 glucose uptake Effects 0.000 claims description 5
- 201000010536 head and neck cancer Diseases 0.000 claims description 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
- 230000001771 impaired effect Effects 0.000 claims description 5
- 208000017169 kidney disease Diseases 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- 231100000794 masculinization Toxicity 0.000 claims description 5
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 201000011682 nervous system cancer Diseases 0.000 claims description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 201000001119 neuropathy Diseases 0.000 claims description 5
- 230000007823 neuropathy Effects 0.000 claims description 5
- 230000011164 ossification Effects 0.000 claims description 5
- 230000001009 osteoporotic effect Effects 0.000 claims description 5
- 201000008968 osteosarcoma Diseases 0.000 claims description 5
- 230000002062 proliferating effect Effects 0.000 claims description 5
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- 230000011664 signaling Effects 0.000 claims description 5
- 201000000849 skin cancer Diseases 0.000 claims description 5
- 208000017520 skin disease Diseases 0.000 claims description 5
- 201000002314 small intestine cancer Diseases 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 208000022345 tetraamelia syndrome Diseases 0.000 claims description 5
- 201000002510 thyroid cancer Diseases 0.000 claims description 5
- 208000037964 urogenital cancer Diseases 0.000 claims description 5
- 230000006496 vascular abnormality Effects 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 208000005410 Mediastinal Neoplasms Diseases 0.000 claims description 4
- 150000001204 N-oxides Chemical class 0.000 claims description 4
- 125000002619 bicyclic group Chemical group 0.000 claims description 4
- 230000000747 cardiac effect Effects 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 208000016097 disease of metabolism Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 150000004677 hydrates Chemical class 0.000 claims description 4
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 201000000349 mediastinal cancer Diseases 0.000 claims description 4
- 125000002950 monocyclic group Chemical group 0.000 claims description 4
- 201000010193 neural tube defect Diseases 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 125000003003 spiro group Chemical group 0.000 claims description 4
- 208000035581 susceptibility to neural tube defects Diseases 0.000 claims description 4
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 125000000593 indol-1-yl group Chemical group [H]C1=C([H])C([H])=C2N([*])C([H])=C([H])C2=C1[H] 0.000 claims description 3
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims description 2
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims description 2
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 125000001607 1,2,3-triazol-1-yl group Chemical group [*]N1N=NC([H])=C1[H] 0.000 claims 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 210000000276 neural tube Anatomy 0.000 claims 1
- 230000001668 ameliorated effect Effects 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000024335 physical disease Diseases 0.000 description 3
- 208000004286 Osteochondrodysplasias Diseases 0.000 description 2
- 201000010096 SOST-related sclerosing bone dysplasia Diseases 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 206010061159 Foot deformity Diseases 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 201000010255 female reproductive organ cancer Diseases 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000032724 odontogenesis Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261607680P | 2012-03-07 | 2012-03-07 | |
| US61/607,680 | 2012-03-07 | ||
| PCT/GB2013/050561 WO2013132253A1 (en) | 2012-03-07 | 2013-03-07 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015512885A JP2015512885A (ja) | 2015-04-30 |
| JP2015512885A5 true JP2015512885A5 (https=) | 2016-03-31 |
| JP6082409B2 JP6082409B2 (ja) | 2017-02-15 |
Family
ID=47891779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014560442A Expired - Fee Related JP6082409B2 (ja) | 2012-03-07 | 2013-03-07 | ３−アリール−５−置換イソキノリン−１−オン化合物及びその治療的使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9193689B2 (https=) |
| EP (1) | EP2822656B1 (https=) |
| JP (1) | JP6082409B2 (https=) |
| KR (1) | KR102104144B1 (https=) |
| CN (1) | CN104302358B (https=) |
| AU (1) | AU2013229229B2 (https=) |
| CA (1) | CA2865511A1 (https=) |
| DK (1) | DK2822656T3 (https=) |
| ES (1) | ES2611504T3 (https=) |
| IN (1) | IN2014MN01875A (https=) |
| MX (1) | MX346147B (https=) |
| RU (1) | RU2696572C2 (https=) |
| WO (1) | WO2013132253A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2865511A1 (en) | 2012-03-07 | 2013-09-12 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| EP2882714B1 (en) | 2012-08-08 | 2019-11-13 | Merck Patent GmbH | (aza-)isoquinolinone derivatives |
| US9611223B2 (en) | 2013-09-11 | 2017-04-04 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| DK3356345T3 (da) * | 2015-09-30 | 2024-02-12 | Max Planck Gesellschaft | Heteroaryl-derivater som sepiapterin-reduktase-inhibitorer |
| CN108289448B (zh) | 2015-12-02 | 2021-10-22 | 先正达参股股份有限公司 | 杀微生物的噁二唑衍生物 |
| UY37623A (es) | 2017-03-03 | 2018-09-28 | Syngenta Participations Ag | Derivados de oxadiazol tiofeno fungicidas |
| EP3630753A1 (en) | 2017-06-02 | 2020-04-08 | Syngenta Participations AG | Microbiocidal oxadiazole derivatives |
| WO2018219773A1 (en) | 2017-06-02 | 2018-12-06 | Syngenta Participations Ag | Fungicidal compositions |
| KR20200022452A (ko) | 2017-06-28 | 2020-03-03 | 신젠타 파티서페이션즈 아게 | 살진균 조성물 |
| WO2019011926A1 (en) | 2017-07-11 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
| BR112020000465B1 (pt) | 2017-07-11 | 2024-02-20 | Syngenta Participations Ag | Derivados oxadiazol microbiocidas |
| WO2019011929A1 (en) | 2017-07-11 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
| WO2019011928A1 (en) | 2017-07-11 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
| WO2019012011A1 (en) | 2017-07-12 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
| WO2019012003A1 (en) | 2017-07-13 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
| EP3459469A1 (en) | 2017-09-23 | 2019-03-27 | Universität Zürich | Medical occluder device |
| US12402885B2 (en) | 2017-09-23 | 2025-09-02 | Universität Zürich | Medical occlusion device |
| AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
| EP3823966A1 (en) | 2018-07-16 | 2021-05-26 | Syngenta Crop Protection AG | Microbiocidal oxadiazole derivatives |
| JP7598875B2 (ja) | 2019-04-12 | 2024-12-12 | リボサイエンス リミティド ライアビリティ カンパニー | エクトヌクレオチドピロホスファターゼホスホジエステラーゼ１阻害剤としての二環式ヘテロアリール誘導体 |
| AR118673A1 (es) | 2019-04-18 | 2021-10-20 | Syngenta Crop Protection Ag | Procedimiento para la preparación de derivados de oxadiazol microbiocidas |
| CN114641242B (zh) | 2019-09-26 | 2025-11-18 | 苏黎世大学 | 左心耳闭塞装置 |
| US12459899B2 (en) * | 2019-10-30 | 2025-11-04 | DIGMBIO, Inc. | Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1-related diseases, comprising the same as active ingredient |
| WO2021191833A1 (en) | 2020-03-25 | 2021-09-30 | Universitat Zurich | Medical occluder delivery systems |
| EP4232925A1 (en) | 2020-10-21 | 2023-08-30 | Verint Americas Inc. | System and method of automated determination of use of sensitive information and corrective action for improper use |
| EP4308664A1 (de) | 2021-03-18 | 2024-01-24 | Merck Patent GmbH | Heteroaromatische verbindungen für organische elektrolumineszenzvorrichtungen |
| CN117642375A (zh) * | 2021-05-04 | 2024-03-01 | 德克萨斯大学系统董事会 | 茚酮与四氢萘酮-酮或羟基肟作为癌症治疗剂 |
| EP4359401A1 (en) * | 2021-06-23 | 2024-05-01 | Blueprint Medicines Corporation | Process for preparing egfr inhibitors |
| KR20240149429A (ko) * | 2022-02-16 | 2024-10-14 | 듀크 스트리트 바이오 리미티드 | 약학적 화합물 |
| CN115572262B (zh) * | 2022-10-27 | 2024-08-27 | 厦门沃克沃德医药科技有限公司 | 一种异喹啉衍生物及其制备方法 |
| WO2024238871A1 (en) * | 2023-05-18 | 2024-11-21 | Rectify Pharmaceuticals, Inc. | Aryl sulfonamide compounds and their use in treating medical conditions |
| GB2634228A (en) * | 2023-10-02 | 2025-04-09 | Duke Street Bio Ltd | PARP1 inhibitor compounds |
| WO2025136936A1 (en) * | 2023-12-19 | 2025-06-26 | Merck Sharp & Dohme Llc | Agonists of trem2 activity |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2851458A (en) | 1955-06-08 | 1958-09-09 | Burroughs Wellcome Co | Diquaternary compounds and the manufacture thereof |
| US3464563A (en) | 1967-02-06 | 1969-09-02 | American Air Filter Co | Liquid filter apparatus |
| US4678500A (en) | 1984-06-29 | 1987-07-07 | E. I. Du Pont De Nemours And Company | Herbicidal 2,6-disubstituted benzylsulfonamides and benzenesulfamates |
| US5177075A (en) | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
| US4942163A (en) | 1989-03-07 | 1990-07-17 | E. I. Du Pont De Nemours And Company | 1(2H)-isoquinolinones and 1-isoquinolineamines as cancer chemotherapeutic agents |
| ATE404539T1 (de) | 1997-10-02 | 2008-08-15 | Eisai R&D Man Co Ltd | Kondensierte pyridinderivate |
| US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| JPWO2002094790A1 (ja) | 2001-05-23 | 2004-09-09 | 三菱ウェルファーマ株式会社 | 縮合ヘテロ環化合物およびその医薬用途 |
| CA2461202C (en) | 2001-09-21 | 2011-07-12 | Donald Pinto | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| MXPA05000983A (es) * | 2002-07-24 | 2005-08-18 | Kyorin Seiyaku Kk | Derivados de 4-(aril substituido)-5-hidroxiisoquinolinona. |
| JP4520406B2 (ja) * | 2002-10-01 | 2010-08-04 | 田辺三菱製薬株式会社 | イソキノリン化合物及びその医薬用途 |
| EA010408B1 (ru) | 2002-10-23 | 2008-08-29 | Гленмарк Фармасьютикалс Лтд. | Трициклические соединения для лечения воспалительных и аллергических нарушений, способы их приготовления и содержащие их фармацевтические составы |
| ATE496893T1 (de) | 2002-12-20 | 2011-02-15 | X Ceptor Therapeutics Inc | Isochinolinonderivate und deren verwendung als medikamente |
| ES2320771T3 (es) | 2003-04-16 | 2009-05-28 | Bristol-Myers Squibb Company | Inhibidores peptidicos de isoquinolina macrociclicos del virus de la hepatitis c. |
| TW200536830A (en) | 2004-02-06 | 2005-11-16 | Chugai Pharmaceutical Co Ltd | 1-(2H)-isoquinolone derivative |
| WO2005075432A1 (ja) | 2004-02-06 | 2005-08-18 | Chugai Seiyaku Kabushiki Kaisha | １−（２ｈ）−イソキノロン誘導体およびその抗ガン剤としての使用 |
| WO2005113540A1 (ja) | 2004-05-20 | 2005-12-01 | Mitsubishi Pharma Corporation | イソキノリン化合物及びその医薬用途 |
| WO2006045010A2 (en) | 2004-10-20 | 2006-04-27 | Resverlogix Corp. | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| ES2611604T3 (es) | 2004-10-22 | 2017-05-09 | Janssen Pharmaceutica Nv | Inhibidores de la c fms quinasa |
| JP2008524131A (ja) | 2004-12-16 | 2008-07-10 | エフ．ホフマン−ラ ロシュ アーゲー | 抗肥満薬としてのピペラジニルピリジン誘導体 |
| TWI389897B (zh) | 2005-02-22 | 2013-03-21 | Chugai Pharmaceutical Co Ltd | 1- (2H) -isoquinolinone derivatives |
| SI1864976T1 (sl) | 2005-03-31 | 2012-12-31 | Astellas Pharma Inc. | Propan-1,3-dionski derivat ali njegova sol |
| CA2617213C (en) | 2005-07-29 | 2014-01-28 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| CN101316592A (zh) | 2005-08-24 | 2008-12-03 | 伊诺泰克制药公司 | 茚并异喹啉酮类似物及其用法 |
| AU2007292155B2 (en) | 2006-09-05 | 2012-11-01 | Kyowa Kirin Co., Ltd. | Imidazole derivative |
| US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2008092231A1 (en) | 2007-02-01 | 2008-08-07 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular diseases |
| FR2919286A1 (fr) * | 2007-07-27 | 2009-01-30 | Sanofi Aventis Sa | Derives de derives de 1-oxo-1,2-dihydroisoquinoleine-5- carboxamides et de 4-oxo-3,4-dihydroquinazoline-8- carboxamides,leur preparation et leur application en therapeutique. |
| US20090054392A1 (en) | 2007-08-20 | 2009-02-26 | Wyeth | Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
| WO2009027650A1 (en) | 2007-08-24 | 2009-03-05 | The Institute Of Cancer: Royal Cancer Hospital | Materials and methods for exploiting synthetic lethality in brca-associated cancers |
| CN101854924A (zh) | 2007-11-05 | 2010-10-06 | 诺瓦提斯公司 | 测量wnt活化以及治疗wnt相关癌症的方法和组合物 |
| DE102008019838A1 (de) | 2008-04-19 | 2009-12-10 | Boehringer Ingelheim International Gmbh | Neue Arylsulfonylglycin-Derivate, deren Herstellung und deren Verwendung als Arzneimittel |
| CA2722035C (en) | 2008-04-22 | 2016-10-11 | Janssen Pharmaceutica Nv | Quinoline or isoquinoline substituted p2x7 antagonists |
| JP5743897B2 (ja) | 2008-11-20 | 2015-07-01 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | 化合物 |
| SG174252A1 (en) | 2009-03-06 | 2011-10-28 | Hoffmann La Roche | Heterocyclic antiviral compounds |
| NZ755378A (en) | 2009-03-18 | 2022-07-29 | Resverlogix Corp | Novel quinazolinones and related compounds for use as anti-inflammatory agents |
| KR20190091564A (ko) | 2009-04-22 | 2019-08-06 | 리스버로직스 코퍼레이션 | 신규한 소염제 |
| TWI499418B (zh) | 2009-05-21 | 2015-09-11 | Nerviano Medical Sciences Srl | 異喹啉－１（２ｈ）－酮衍生物 |
| EP2488520B1 (en) | 2009-10-13 | 2015-09-02 | Merck Sharp & Dohme B.V. | Condensed azine-derivatives for the treatment of diseases related to the acetylcholine receptor |
| CA2799579A1 (en) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| CN102947274A (zh) | 2010-06-17 | 2013-02-27 | 诺瓦提斯公司 | 联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物 |
| EP2731940B1 (en) | 2011-07-13 | 2015-08-19 | Novartis AG | 4 - piperidinyl compounds for use as tankyrase inhibitors |
| CN103814032A (zh) | 2011-07-13 | 2014-05-21 | 诺华股份有限公司 | 用作端锚聚合酶抑制剂的4-氧代-3,5,7,8-四氢-4H-吡喃并[4,3-d]嘧啶基化合物 |
| US9181266B2 (en) | 2011-07-13 | 2015-11-10 | Novartis Ag | 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors |
| IN2014CN04671A (https=) | 2011-11-25 | 2015-09-18 | Nerviano Medical Sciences Srl | |
| IN2014DN06169A (https=) | 2011-12-31 | 2015-08-21 | Beigene Ltd | |
| MX2014008071A (es) | 2011-12-31 | 2015-07-06 | Beigene Ltd | Tetra o penta-piridoftalazinonas ciclicas fusionadas como inhibidores de poli(adenosin-difosfato-ribosa)polimerasas. |
| HK1202543A1 (en) | 2012-01-28 | 2015-10-02 | Merck Patent Gmbh | Azaheterocyclic compounds |
| WO2013116182A1 (en) | 2012-01-31 | 2013-08-08 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds as inhibitors of leukotriene production |
| KR20140121477A (ko) | 2012-02-09 | 2014-10-15 | 메르크 파텐트 게엠베하 | Ｔａｎｋ 및 ｐａｒｐ 저해체로서의 테트라히드로-퀴나졸리논 |
| US9340549B2 (en) | 2012-03-05 | 2016-05-17 | Amgen Inc. | Oxazolidinone compounds and derivatives thereof |
| CA2865511A1 (en) | 2012-03-07 | 2013-09-12 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| MX351149B (es) | 2012-03-28 | 2017-10-04 | Merck Patent Gmbh | Derivados biciclicos de pirazinona. |
| US20130281397A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| CN104271580B (zh) | 2012-05-04 | 2017-02-22 | 默克专利股份公司 | 吡咯并三嗪酮衍生物 |
| WO2013177349A2 (en) | 2012-05-25 | 2013-11-28 | Glaxosmithkline Llc | Quinazolinediones as tankyrase inhibitors |
| CN104540830A (zh) | 2012-06-07 | 2015-04-22 | 霍夫曼-拉罗奇有限公司 | 端锚聚合酶的吡唑并嘧啶酮和吡唑并吡啶酮抑制剂 |
| WO2013182580A1 (en) | 2012-06-07 | 2013-12-12 | F. Hoffmann-La Roche Ag | Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase |
| RU2014152790A (ru) | 2012-06-20 | 2016-08-10 | Ф. Хоффманн-Ля Рош Аг | Пирролопиразоновые ингибиторы танкиразы |
| HK1201066A1 (en) | 2012-06-20 | 2015-08-21 | 霍夫曼-拉罗奇有限公司 | Pyranopyridone inhibitors of tankyrase |
| EP2882714B1 (en) | 2012-08-08 | 2019-11-13 | Merck Patent GmbH | (aza-)isoquinolinone derivatives |
| WO2014036022A1 (en) | 2012-08-29 | 2014-03-06 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
| WO2014045101A1 (en) | 2012-09-21 | 2014-03-27 | Cellzome Gmbh | Tetrazolo quinoxaline derivatives as tankyrase inhibitors |
| AR092211A1 (es) | 2012-09-24 | 2015-04-08 | Merck Patent Ges Mit Beschränkter Haftung | Derivados de hidropirrolopirrol |
| JP6276769B2 (ja) | 2012-09-26 | 2018-02-07 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｐａｒｐインヒビターとしてのキナゾリノン誘導体 |
| WO2014087165A1 (en) | 2012-12-06 | 2014-06-12 | University Of Bath | Tankyrase inhibitors |
-
2013
- 2013-03-07 CA CA2865511A patent/CA2865511A1/en not_active Abandoned
- 2013-03-07 CN CN201380023162.0A patent/CN104302358B/zh not_active Expired - Fee Related
- 2013-03-07 DK DK13709994.1T patent/DK2822656T3/en active
- 2013-03-07 MX MX2014010509A patent/MX346147B/es active IP Right Grant
- 2013-03-07 WO PCT/GB2013/050561 patent/WO2013132253A1/en not_active Ceased
- 2013-03-07 KR KR1020147026143A patent/KR102104144B1/ko not_active Expired - Fee Related
- 2013-03-07 US US14/381,712 patent/US9193689B2/en not_active Expired - Fee Related
- 2013-03-07 EP EP13709994.1A patent/EP2822656B1/en active Active
- 2013-03-07 IN IN1875MUN2014 patent/IN2014MN01875A/en unknown
- 2013-03-07 JP JP2014560442A patent/JP6082409B2/ja not_active Expired - Fee Related
- 2013-03-07 RU RU2014138194A patent/RU2696572C2/ru not_active Application Discontinuation
- 2013-03-07 AU AU2013229229A patent/AU2013229229B2/en not_active Ceased
- 2013-03-07 ES ES13709994.1T patent/ES2611504T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015512885A5 (https=) | ||
| JP2016531153A5 (https=) | ||
| RU2014138194A (ru) | 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение | |
| JP6388915B2 (ja) | 置換５−（３，５−ジメチルイソオキサゾール−４−イル）インドリン−２−オン | |
| AU2020322026B2 (en) | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | |
| DE60005850T2 (de) | Imidazo[1,2-a]pyridin- und pyrazolo[2,3-a]pyridinderivate | |
| EP2531502B1 (en) | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy | |
| CN105189514A (zh) | 作为bet-蛋白抑制剂用于治疗过度增殖性疾病的吡咯并-和吡唑并-三唑并二氮杂卓 | |
| JP2013503193A (ja) | Ｒａｆ阻害剤化合物およびその使用方法 | |
| EA032621B1 (ru) | Индазолкарбоксамиды, способы их получения, содержащие их фармацевтические препараты и их применение для изготовления лекарственных средств | |
| EP1803723A1 (de) | (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximid derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs | |
| JP2020518672A (ja) | キナーゼ阻害活性を有する化合物、その製造方法及び用途 | |
| UA118989C2 (uk) | Дигідропіролопіридинові інгібітори ror-гамма | |
| AU2016214492B2 (en) | 2-phenyl-3H-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ROR1activity | |
| JP2013545779A (ja) | 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン | |
| HK1215250A1 (zh) | 氨基取代的异噻唑 | |
| JP2021500340A (ja) | ＰＩ３Ｋ−γ阻害剤としての三級ヒドロキシ基で置換された縮合イミダゾール誘導体 | |
| AU2019295765B2 (en) | Proteasome activity enhancing compounds | |
| JP2018501250A (ja) | Ｍｋｎｋ１およびｍｋｎｋ２阻害剤としてのピラゾロピリジンアミン | |
| KR20160019426A (ko) | 암의 치료를 위한 신규 화합물 | |
| JP2017517516A (ja) | ベンゾチアジアゾールアミン | |
| US7888380B2 (en) | 1,2,4-Triazolylaminoaryl (heteroaryl) sulfonamide derivatives | |
| ES2850773T3 (es) | Piridincarboxamidas como inhibidores de GSK-3 | |
| EP2977375A1 (en) | Amino-substituted isoxazoles | |
| TWI664179B (zh) | 經取代之５－（３，５－二甲基異唑－４－基）二氫吲哚－２－酮 |